Navigation Links
CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates
Date:3/2/2015

SOUTH SAN FRANCISCO, Calif., March 2, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the creation of scientific and clinical advisory boards comprised of leading researchers and clinicians in the fields of cancer immunotherapy and antibody drug conjugates.

The new advisory boards will provide guidance to CytomX on the development of its wholly owned pipeline of precision immunotherapies and Probody drug conjugates. The company identified advisors who have led significant advances in their respective fields, both in the research and clinical settings. These advisory boards will augment the company's existing platform scientific advisory board, which will remain focused on continued development of the Probody technology platform.

"Our Probody technology enables a wide array of therapeutic antibody modalities, including immunotherapies, Probody drug conjugates, bispecifics and engineered T-cell therapies. We are excited to be working with such accomplished advisors as we move our proprietary pipeline towards the clinic," said Sean McCarthy, D. Phil., chief executive officer of CytomX. "Our advisory boards will be instrumental in helping us design translational clinical strategies to achieve proof of concept for our highly differentiated programs." 

Immunotherapy Advisory Board

Antibody Drug Conjugate Advisory Board

About CytomX Therapeutics

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a seasoned and proven management team and is financed by leading life science investors, including Third Rock Ventures, Canaan Partners, Roche Venture Fund and Pfizer Venture Investments. For more information, please visit www.cytomx.com.

Media Contacts:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388

 


'/>"/>
SOURCE CytomX Therapeutics
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lehigh Valley Expands Fleet of Superbug-Slaying Robots
2. Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer
3. Fortune 500 Pharmaceutical Company Expands Use of inContact Cloud Contact Center Software Across Multiple Divisions
4. BioDrain Breaks into National Network of Ambulatory Surgical Centers and Expands Installations of its STREAMWAY System throughout the U.S.
5. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
6. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
7. NextDocs Expands Customer Roster by More Than 10 Percent
8. Sotera Wireless Expands Board Of Directors
9. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
10. Senior Home Care Expands Home Health Telemonitoring into Spring Hill, Fla.
11. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... ... January 03, 2020 , ... In Partnership with the Smiles for ... underinsured individuals at its Burleson, TX office on February 8th. , Dental services provided ... cleanings and extractions . For more information, please visit the Monarch ...
(Date:1/3/2020)... (PRWEB) , ... January 03, 2020 , ... ... division by Montreal-based AlayaCare. The combined business will offer enterprise solutions for ... acquire all Procura assets, people and customer contracts and will move forward under ...
(Date:1/2/2020)... ... January 02, 2020 , ... ... address all levels of psychiatric-mental health nursing administration, education, practice, and research. ... 1800+ registered and advanced practice nurses. Nurses from varied backgrounds are encouraged ...
Breaking Medicine Technology:
(Date:1/12/2020)... ... January 12, 2020 , ... Cecelia Health ... York City, has continually innovated for over a decade to transform lives and ... device companies and self-insured employers. By optimizing the mix of expert clinician and ...
(Date:1/10/2020)... ... January 10, 2020 , ... Ziegler, a specialty investment bank, ... Ltd. on its partnership with US Radiology Specialists (“USRS”), backed by private equity ... is the largest private practice radiology group and outpatient imaging operator in Tucson, ...
(Date:1/10/2020)... ... January 10, 2020 , ... The value of healthy vision ... via a preventative approach. Leading eye care doctor, Brent Bellotte MD., champions such proactive ... common eye diseases. , Eyesight is something that many take for granted until a ...
(Date:1/10/2020)... ... January 10, 2020 , ... The Board of ... Emergency Nurse (CPEN) specialty nursing certification program has been reaccredited by the ... national board certification earned by registered nurses (RNs) who demonstrate advanced knowledge ...
(Date:1/8/2020)... ... January 08, 2020 , ... Mirror Mirror Beauty ... 2019 Best of Memorial Readers’ Choice Awards. Located adjacent to Vitenas Cosmetic ... MedSpa in Memorial reflects Mirror Mirror Beauty Boutique’s commitment to the hottest noninvasive ...
Breaking Medicine News(10 mins):